Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers.
T cell immunology
chimeric antigen receptor
co-stimulation
immunotherapy
Journal
Immunotherapy advances
ISSN: 2732-4303
Titre abrégé: Immunother Adv
Pays: England
ID NLM: 101776979
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
28
05
2021
revised:
22
07
2021
accepted:
30
07
2021
entrez:
3
8
2022
pubmed:
4
8
2022
medline:
4
8
2022
Statut:
epublish
Résumé
Co-stimulation is a fundamental component of T cell biology and plays a key role in determining the quality of T cell proliferation, differentiation, and memory formation. T cell-based immunotherapies, such as chimeric antigen receptor (CAR) T cell immunotherapy, are no exception. Solid tumours have largely been refractory to CAR T cell therapy owing to an immunosuppressive microenvironment which limits CAR T cell persistence and effector function. In order to eradicate solid cancers, increasingly sophisticated strategies are being developed to deliver these vital co-stimulatory signals to CAR T cells, often specifically within the tumour microenvironment. These include designing novel co-stimulatory domains within the CAR or other synthetic receptors, arming CAR T cells with cytokines or using CAR T cells in combination with agonist antibodies. This review discusses the evolving role of co-stimulation in CAR T cell therapies and the strategies employed to target co-stimulatory pathways in CAR T cells, with a view to improve responses in solid tumours.
Identifiants
pubmed: 35919743
doi: 10.1093/immadv/ltab016
pii: ltab016
pmc: PMC9327106
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
ltab016Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology.
Références
Cancer Res. 2009 Jun 15;69(12):4941-4
pubmed: 19509221
J Virol. 2018 Nov 12;92(23):
pubmed: 30232179
Cancer Discov. 2021 Jul;11(7):1661-1671
pubmed: 33563660
Blood. 2016 Jul 28;128(4):519-28
pubmed: 27226436
Nature. 2014 Mar 27;507(7493):519-22
pubmed: 24531764
Cancer Biol Ther. 2020 Jun 2;21(6):570-580
pubmed: 32208880
J Immunother Cancer. 2018 May 10;6(1):34
pubmed: 29747685
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19501-6
pubmed: 24218606
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
pubmed: 17062687
Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25229-25235
pubmed: 31767744
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33504576
Hum Gene Ther. 2007 Jul;18(7):589-602
pubmed: 17630837
Cancer Res. 2004 May 1;64(9):3281-7
pubmed: 15126371
iScience. 2020 Apr 24;23(4):101023
pubmed: 32325413
Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137
pubmed: 32451681
Cancer Cell. 2019 Mar 18;35(3):473-488.e6
pubmed: 30889381
JCI Insight. 2020 Nov 5;5(21):
pubmed: 33148882
Immunotherapy. 2013 Jul;5(7):677-81
pubmed: 23829616
Science. 2020 Jan 24;367(6476):446-453
pubmed: 31896660
Clin Transl Immunology. 2019 May 11;8(5):e1049
pubmed: 31110702
Nat Biotechnol. 2018 Apr;36(4):346-351
pubmed: 29505028
Nat Biotechnol. 2018 Oct;36(9):847-856
pubmed: 30102295
Cancer Res. 2017 Mar 15;77(6):1296-1309
pubmed: 28082401
Immunity. 2019 Apr 16;50(4):832-850
pubmed: 30995502
Nature. 2016 Jun 01;534(7607):396-401
pubmed: 27281205
Nat Biotechnol. 2002 Jan;20(1):70-5
pubmed: 11753365
Hum Gene Ther. 2005 Mar;16(3):348-60
pubmed: 15812230
Cancer Res. 2016 Mar 15;76(6):1578-90
pubmed: 26979791
J Leukoc Biol. 2010 Jun;87(6):989-99
pubmed: 20179153
Blood. 2012 Jan 19;119(3):696-706
pubmed: 22117050
Science. 2019 Jul 12;365(6449):162-168
pubmed: 31296767
Leukemia. 2018 Mar;32(3):801-808
pubmed: 28841215
Cell Rep. 2017 Dec 12;21(11):3205-3219
pubmed: 29241547
Leuk Res. 2009 Nov;33(11):1485-9
pubmed: 19243818
Oncoimmunology. 2012 Jul 1;1(4):547-549
pubmed: 22754782
Int J Oncol. 2008 Apr;32(4):777-89
pubmed: 18360705
Nat Rev Immunol. 2005 Dec;5(12):928-40
pubmed: 16322746
Cancer Discov. 2018 Jan;8(1):5-6
pubmed: 29113977
J Immunol. 2013 Oct 15;191(8):4121-9
pubmed: 24026081
J Thorac Dis. 2020 Aug;12(8):4510-4515
pubmed: 32944365
Hum Gene Ther. 2014 Dec;25(12):1003-12
pubmed: 24694017
Eur J Immunol. 2009 Oct;39(10):2673-81
pubmed: 19634192
Cancer Cell. 2020 Feb 10;37(2):216-225.e6
pubmed: 32004441
Nat Med. 2018 Mar;24(3):352-359
pubmed: 29400710
Hum Gene Ther. 1999 Aug 10;10(12):1941-51
pubmed: 10466628
J Immunother Cancer. 2021 May;9(5):
pubmed: 34035114
Mol Ther. 2018 Dec 5;26(12):2727-2737
pubmed: 30309819
J Immunother. 2008 Oct;31(8):714-22
pubmed: 18779748
Annu Rev Med. 2020 Jan 27;71:47-58
pubmed: 31412220
Sci Transl Med. 2019 Apr 10;11(487):
pubmed: 30971453
J Transl Med. 2021 Feb 18;19(1):82
pubmed: 33602263
Sci Transl Med. 2019 Jun 12;11(496):
pubmed: 31189721
FEBS J. 2018 Jul;285(13):2377-2401
pubmed: 29656546
Adv Exp Med Biol. 2019;1189:3-23
pubmed: 31758529
Immunol Rev. 2009 May;229(1):152-72
pubmed: 19426221
Exp Mol Med. 2019 Dec 11;51(12):1-9
pubmed: 31827070
Leukemia. 2019 Sep;33(9):2195-2207
pubmed: 30816327
Clin Transl Immunology. 2020 Jul 22;9(7):e1157
pubmed: 32704371
Leukemia. 2021 Feb;35(2):506-521
pubmed: 32447345
Immunol Rev. 2014 Jan;257(1):83-90
pubmed: 24329791
Sci Adv. 2019 Dec 11;5(12):eaay1357
pubmed: 31844672
Cancer Immunol Res. 2018 May;6(5):605-616
pubmed: 29588319
Mol Ther. 2018 Apr 4;26(4):976-985
pubmed: 29503204
Cancer Res. 2011 Sep 1;71(17):5697-706
pubmed: 21742772
Clin Transl Immunology. 2020 Aug 15;9(8):e1165
pubmed: 32821382
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3029-34
pubmed: 14981245
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cancer Immunol Res. 2020 Jun;8(6):732-742
pubmed: 32213625
Mol Ther Oncolytics. 2019 Nov 02;15:234-247
pubmed: 31872046
Front Biosci (Landmark Ed). 2018 Jun 1;23(12):2245-2254
pubmed: 29772559
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369
J Clin Invest. 1998 Mar 15;101(6):1441-52
pubmed: 9502787
PLoS One. 2013 May 07;8(5):e63037
pubmed: 23667569